Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Generic substitution: issues for problematic drugs.

J D Henderson1, R H Esham

  • 1Department of Physician Assistant Studies, College of Allied Health Professions, University of South Alabama College of Medicine, Mobile, USA.

Southern Medical Journal
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian recommendations for the management of breakthrough cancer pain.

Current oncology (Toronto, Ont.)·2016
Same author

Evaluation of a fluorescent method for measuring cholinesterase activity in mammalian blood and tissue.

Bulletin of environmental contamination and toxicology·2007
Same author

The costimulatory molecules CD80, CD86 and OX40L are up-regulated in Aspergillus fumigatus sensitized mice.

Clinical and experimental immunology·2005
Same author

Organophosphate dormant spray pest control efficacy, pesticide concentration and toxicity in storm runoff.

Bulletin of environmental contamination and toxicology·2004
Same author

Spatial distribution and temporal onset of NF-kB activation and inducible nitric oxide synthase within pancreatic islets in the pre-diabetic stage of genetic, diabetic-prone BB rats: attenuation by drug intervention decreases inflammatory cell infiltration and incidence of diabetes.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2004
Same author

Correction: generic substitution.

Southern medical journal·2002
Same journal

SMA's 6th Annual Physicians-in-Training Leadership Conference Abstract Presentations.

Southern medical journal·2026
Same journal

Potential Impact of Lower Federal Loan Availability on Medical Education in Appalachia.

Southern medical journal·2026
Same journal

Experiential Mentorship Skills Training: The Effect on Real-Life Mentoring.

Southern medical journal·2026
Same journal

Social Pressure: How Early Social Context Shapes Career Interest in Medicine.

Southern medical journal·2026
Same journal

Comparing Speed and Accuracy of Artificial Intelligence Large Language Models on the Orthopedic In-Training Examination.

Southern medical journal·2026
Same journal

Don't Wait to Talk about Weight: A 2-Hour Interactive Curriculum Improves Medical Student Skills with Weight Management.

Southern medical journal·2026
See all related articles

The Food and Drug Administration (FDA) ensures generic drug bioequivalence. However, some narrow therapeutic index drugs like digoxin and levothyroxine lack FDA-determined therapeutic equivalence, despite myths suggesting otherwise.

Area of Science:

  • Pharmacokinetics and Pharmaceutical Sciences
  • Drug Regulatory Affairs

Background:

  • The U.S. Food and Drug Administration (FDA) has established rigorous bioequivalence testing methodologies and criteria.
  • Certain drugs, particularly those with a narrow therapeutic index (NTI), may pose challenges for generic substitution due to state-specific laws and safety concerns.
  • Examples of NTI drugs include digoxin, levothyroxine, and warfarin.

Purpose of the Study:

  • To examine the FDA's established bioequivalence criteria and their application to drugs with a narrow therapeutic index.
  • To address persistent misinformation regarding the FDA's determination of bioequivalence for specific generic medications.
  • To clarify the therapeutic equivalence status of generic digoxin, levothyroxine, warfarin, and albuterol products.

Main Methods:

Related Experiment Videos

  • Review of FDA guidelines and established methodologies for bioequivalence testing.
  • Analysis of the regulatory status and FDA determinations for generic versions of digoxin, levothyroxine, warfarin, and albuterol.
  • Identification and evaluation of common misconceptions surrounding FDA bioequivalence assessments.

Main Results:

  • No New Drug Applications (NDAs) currently exist for digoxin and levothyroxine tablets.
  • Commercially available generic digoxin and levothyroxine products have not been determined by the FDA to be therapeutically equivalent to their innovator counterparts.
  • Generic warfarin and albuterol (rescue inhaler) have received FDA approval as therapeutically equivalent to innovator products, yet public misinformation persists.

Conclusions:

  • While FDA bioequivalence standards are robust, therapeutic equivalence for some NTI drugs remains a complex issue.
  • Public understanding of FDA's role in ensuring generic drug safety and efficacy, especially for NTI drugs, requires clarification.
  • Continued vigilance and accurate dissemination of information are crucial to combat myths surrounding generic drug bioequivalence.